
A daily vitamin most people associate with bone health and immune support just showed up somewhere unexpected: helping chemotherapy work better against breast cancer. In a small clinical trial out of Brazil, women who took a modest daily dose of vitamin D alongside their chemotherapy were significantly more likely to have no detectable cancer left in their tumor tissue afterward than women who took a placebo.
Key Takeaways
- In a randomized trial of 80 women with breast cancer, those who took 2,000 IU of vitamin D daily during chemotherapy had a 43% rate of pathologic complete response — no detectable cancer left in tissue after surgery — compared to 24% in the placebo group.
- “Pathologic complete response” is a strong biomarker linked to better long-term survival, though not an absolute guarantee against recurrence.
- A separate, independent trial in Turkey using a different, higher weekly dose found a similar pattern, lending real support to the Brazilian findings.
- This was a small trial, and researchers themselves are calling for larger studies before this becomes a standard recommendation.
What the Researchers Did
The trial, led by researchers at Botucatu Medical School at São Paulo State University (UNESP) and published in the journal Nutrition and Cancer, enrolled 80 women over age 45 who were about to begin neoadjuvant chemotherapy — chemotherapy given before surgery specifically to shrink a tumor and make it easier to remove. Participants were randomly split into two equal groups: 40 received a daily 2,000 IU dose of vitamin D, while the other 40 received a placebo, alongside their standard chemotherapy regimen. Seventy-five women completed the full six-month course.
What “No Detectable Cancer” Actually Means
After surgery, doctors examined the removed tissue for any remaining cancer cells — what’s called a pathologic complete response, or pCR, when none are found. In the vitamin D group, 43% achieved this; in the placebo group, 24% did, a statistically significant difference. Researchers also found that the higher a woman’s vitamin D blood levels climbed during treatment, the more likely she was to reach this outcome. It’s worth understanding what pCR does and doesn’t tell us: it’s one of the strongest available predictors of better long-term survival after breast cancer treatment, but it isn’t a guarantee of a permanent cure — a small number of cancer cells can occasionally survive undetected and cause recurrence later, even after a pathologic complete response.
This Isn’t the Only Study Pointing This Direction
A separate, independently conducted randomized trial in Turkey, involving a larger group of 227 women, tested a different dosing approach — 50,000 IU of vitamin D3 given once a week rather than a smaller daily dose — and also found a significantly higher pathologic complete response rate in the vitamin D group, with women who took it roughly twice as likely to achieve it. Two independently run trials, using different doses and different patient populations, finding a similar pattern adds real weight to the idea that this effect isn’t just a statistical fluke specific to one small study.
Why Vitamin D Might Help Chemotherapy Work Better
Researchers point to research in cancer cells and animal models suggesting vitamin D can enhance how effectively certain chemotherapy drugs kill cancer cells, potentially through effects on cell growth signaling and immune function. That mechanistic groundwork gives the clinical trial results a plausible biological explanation, though the exact pathway in human patients isn’t fully mapped out yet.
Why This Isn’t a Reason to Self-Prescribe High-Dose Vitamin D
Both trials studied specific, medically supervised doses as part of a structured protocol — not an invitation to take large amounts of vitamin D on your own. Excess vitamin D can cause real toxicity, including dangerously elevated blood calcium levels, and the Brazilian researchers specifically noted their dose was well below the high-dose regimens sometimes used to treat vitamin D deficiency in clinical settings. The researchers themselves were measured about their own findings, noting that even with a small sample size, they observed a meaningful difference — language that reflects genuine promise without overstating what an 80-person trial can prove.
What’s Next
Researchers are calling for larger, multi-center trials to confirm these results and better establish optimal dosing before this could become a standard part of breast cancer treatment protocols. In the meantime, if you or someone you know is undergoing chemotherapy, this is a reasonable, evidence-backed question to raise with an oncologist — including whether checking and addressing vitamin D levels specifically might be worthwhile — rather than something to act on independently.
Sources: Omodei, M.S., et al. (2025). Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial. Nutrition and Cancer, 77(6), 648; Özkurt, E., et al. (2025). Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response. World Journal of Surgery; EurekAlert/FAPESP, “Vitamin D increases the likelihood that breast cancer will disappear with chemotherapy.”

